Recently Viewed
Clear All
$502 Mln
--
2.55
--
0
-1 %
335.44 %
0 %
--
-2128446
$-338.20 Mln
$-392.50 Mln
$-491.26 Mln
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
Prime Medicine
| -53.72 | 16.81 | -9.29 | -47.16 | -- | -- | -- |
BSE Sensex*
| 10.05 | -1.91 | 0.04 | 22.42 | 9.79 | 14.35 | 11.05 |
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
2023
|
|
---|---|
Prime Medicine
| -52.31 |
S&P Small-Cap 600
| 13.89 |
BSE Sensex
| 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
--
--Min --Median --Max
--
--Min --Median --Max
--
Earnings Yield (%) = EBIT / Enterprise value
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
---|---|---|---|---|
2.67 | 224.56 | -- | -1695.99 | |
7.52 | 494.99 | -- | -72.84 | |
8.31 | 563.53 | -- | -8.05 | |
20.80 | 502.78 | -- | -13.06 |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas... protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts. Address: 21 Erie Street, Cambridge, MA, United States, 02139 Read more
The total asset value of Prime Medicine Inc stood at $ 280 Mln as on 30-Jun-24
The share price of Prime Medicine Inc is $4.10 (NASDAQ) as of 07-Nov-2024 16:00 EST. Prime Medicine Inc has given a return of -47.16% in the last 1 years.
Prime Medicine Inc has a market capitalisation of $ 502 Mln as on 06-Nov-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Prime Medicine Inc is 2.55 times as on 06-Nov-2024, a 3% discount to its peers’ median range of 2.63 times.
Since, TTM earnings of Prime Medicine Inc is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Prime Medicine Inc and enter the required number of quantities and click on buy to purchase the shares of Prime Medicine Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts. Address: 21 Erie Street, Cambridge, MA, United States, 02139
The CEO & director of Dr. Keith Michael Gottesdiener Ph.D.. is Prime Medicine Inc, and CFO & Sr. VP is Dr. Keith Michael Gottesdiener M.D., Ph.D..
There is no promoter pledging in Prime Medicine Inc.
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
59
|
|
50
|
|
49
|
|
23
|
Prime Medicine Inc | Ratios |
---|---|
Return on equity(%)
|
-131.92
|
Operating margin(%)
|
-296.99
|
Net Margin(%)
|
-331.49
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Prime Medicine Inc was $0 Mln.